Filgotinib meets in Phase III FINCH 2 study for RA

Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said both doses of filgotinib met the primary and all key secondary endpoints in the Phase III FINCH 2 trial to treat rheumatoid arthritis. Filgotinib is

Read the full 352 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE